The market for ankylosing hyperostosis (AH) treatments is driven by the increasing recognition of the condition and advancements in diagnostic and therapeutic approaches. Over the years, research and clinical trials have improved the understanding of AH, resulting in the development of better treatment options. Conventional treatments focus on pain management through nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and analgesics, while physical therapy and surgery are also used to manage symptoms and improve mobility. Technological advancements in imaging techniques, such as MRI and X-rays, have enabled earlier detection of AH, facilitating timely interventions. In addition, advancements in molecular biology have led to the exploration of targeted therapies, including the potential use of biologics and gene therapy. As healthcare infrastructure continues to grow, particularly in emerging markets, there is increased access to better diagnostic tools and treatments, further driving market growth. The market is expected to expand with a focus on improving patient outcomes and advancing personalized medicine for AH management.
